Raleigh.

PositionREGIONALREPORT Triangle - DARA Biosciences and Innocutis Holdings - Brief article

RALEIGH--DARA Biosciences reached an agreement with Charleston, S.C-based Innocutis Holdings for the commercial rights to sell its drug Bionect on the oncology market to treat patients who develop skin irritations from cancer treatments. The medicine was being sold only in the dermatology market. Terms of the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT